Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00834366
Recruitment Status : Completed
First Posted : February 3, 2009
Results First Posted : June 8, 2009
Last Update Posted : April 30, 2012
Information provided by:
Labopharm Inc.

Brief Summary:
To determine whether the test product, Labopharm Tramadol HCl Once-A-Day (OAD) 200 mg film-coated tablets, and the reference product, Labopharm Tramadol HCl OAD 200 mg uncoated tablets, are bioequivalent.

Condition or disease Intervention/treatment Phase
Healthy Drug: Tramadol HCl Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Study Start Date : February 2005
Actual Primary Completion Date : March 2005
Actual Study Completion Date : March 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tramadol HCl 200 mg Film-coated Tablets
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
Drug: Tramadol HCl
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.

Experimental: Tramadol HCl 200 mg Uncoated Tablets
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
Drug: Tramadol HCl
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.

Primary Outcome Measures :
  1. AUC(0-t) [ Time Frame: 48 hours ]
    Area under plasma concentration versus time curve to the last measurable concentration. Unit is ng.h/mL. h=hours.

  2. AUC(0-Inf) [ Time Frame: 48 hours ]
    Area under plasma concentration versus time curve extrapolated to infinity. Unit is ng.h/mL. h=hour.

  3. Cmax [ Time Frame: 48 hours ]
    Maximum plasma concentration

Secondary Outcome Measures :
  1. Tmax [ Time Frame: 48 hours ]
    Time to the maximum concentration

  2. t1/2 [ Time Frame: 48 hours ]
    Apparent terminal elimination half-life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and female subjects 18 to 55 years of age (inclusive).
  • Body mass within 10% of the ideal mass in relation to height and age, according to the Body Mass Index (BMI).
  • Body mass not less than 60 kg.
  • Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the "normal ranges" for the relevant laboratory tests (unless the investigator considered the deviation to be irrelevant for the purpose of the study).
  • Normal electrocardiogram (ECG) and vital signs, or abnormalities which the investigator did not consider a disqualification for participation in the study.
  • Willingness to undergo a pre-study physical examination and pre- and post-study laboratory investigations.
  • Ability to comprehend and willingness to sign both statements of informed consent (for screening and phase-related procedures).
  • Non-smoker or past smoker who stopped smoking at least 3 months before entering the study.
  • For females, the following conditions were to be met:

    • had been postmenopausal for at least 2 years, or
    • had been surgically sterilized, or
    • was of childbearing potential, and all of the following conditions were met:

      • had a normal menstrual flow within 1 month before study entry, and
      • had negative serum pregnancy test at screening. If this test was positive, the subject was to have been excluded from the study before receiving study medication. In the rare circumstance that a pregnancy was discovered after the subjects received study drug, then every attempt must be made to follow such subjects to term, and
      • must agree to use an accepted method of contraception (i.e., spermicide and barrier methods or spermicide and Intrauterine Device (IUD)). The subject had to agree to continue with the same method throughout the study. Hormonal contraceptives will not be allowed.

Exclusion Criteria:

  • Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  • History of, or current compulsive alcohol abuse (>10 drinks weekly), or regular exposure to other substances of abuse.
  • Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the first administration of study medication except if this would not have affected the outcome of the study in the opinion of the clinical investigator. Use of hormonal contraceptive agents by females were not allowed.
  • Participation in another study with an experimental drug within 8 weeks before the first administration of study medication.
  • Treatment within the previous 3 months with any drug with a well-defined potential for adversely affecting a major organ or system with evidence to this effect.
  • A major illness during the 3 months before commencement of the screening period.
  • History of hypersensitivity to the study drug or any related drugs.
  • History of bronchial asthma.
  • History of epilepsy.
  • Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.
  • Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of study medication.
  • Diagnosis of hypotension made during the screening period.
  • Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.
  • Resting pulse of >100 beats per minute or <45 beats per minute during the screening period, either supine or standing.
  • Positive testing for hepatitis B antigen.
  • Significant liver disease, defined as active hepatitis or elevated liver enzymes (e.g., AST (aspartate aminotransferase), Alanine transaminase (ALT)) >2 times the upper boundary of the normal range.
  • Positive urine screen for drugs of abuse.
  • Positive urine screen for tobacco use (SureStepTM Smoke Check Tests and One-Step Cotinine (COT) Tests).
  • A serum pregnancy test (beta-hCG) either positive or not performed or lactation.
  • History of marijuana, barbiturate, amphetamine or narcotic abuse within 12 months prior to study start.
  • Participation in a tramadol study within the previous 12 months.

Additional Information:
Layout table for additonal information
Responsible Party: Sybil Robertson, Vice President, Regulatory Affairs, Labopharm Inc. Identifier: NCT00834366    
Other Study ID Numbers: MDT1-013
First Posted: February 3, 2009    Key Record Dates
Results First Posted: June 8, 2009
Last Update Posted: April 30, 2012
Last Verified: April 2012
Keywords provided by Labopharm Inc.:
Healthy volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents